Top 6 Brain Regeneration startups in UK
Feb 10, 2026
|
Like
26
1
Funding: $60M
Aerska develops RNA-based therapies to treat, slow and prevent brain diseases. The company uses blood-brain barrier drug delivery technology to deliver targeted RNA interference-based drugs to treat neurological diseases. This technology serves as a drug delivery platform that transports RNAi across the blood-brain barrier. The technology works by creating antibodies or molecules that bind to specific receptors on the surface of the blood-brain barrier. This action tricks the barrier, allowing the therapeutic agent to pass through endothelial cells and enter the brain parenchyma.
Aerska develops RNA-based therapies to treat, slow and prevent brain diseases. The company uses blood-brain barrier drug delivery technology to deliver targeted RNA interference-based drugs to treat neurological diseases. This technology serves as a drug delivery platform that transports RNAi across the blood-brain barrier. The technology works by creating antibodies or molecules that bind to specific receptors on the surface of the blood-brain barrier. This action tricks the barrier, allowing the therapeutic agent to pass through endothelial cells and enter the brain parenchyma.
2
Funding: $40.3M
WaveBreak Therapeutics is a biopharmaceutical company based, focused on drug discovery and development for protein misfolding diseases.
WaveBreak Therapeutics is a biopharmaceutical company based, focused on drug discovery and development for protein misfolding diseases.
3
Funding: $28.4M
Oxford Endovascular are developing a novel treatment for treating brain aneurysms.
Oxford Endovascular are developing a novel treatment for treating brain aneurysms.
4
Magstim has always been at the cutting edge of the evolution of transcranial magnetic stimulation (TMS) from its conception as a valuable research tool to its coming of age as a revolutionary treatment for nerve and brain disorders such as major depressive disorder (MDD).
5
Funding: £12.5M
Shift Bioscience is creating new drug targets and diagnostic tools to enhance healthy lifespan through the repair of mitochondrial genes that cause neurodegenerative diseases or coronary heart disease.
Shift Bioscience is creating new drug targets and diagnostic tools to enhance healthy lifespan through the repair of mitochondrial genes that cause neurodegenerative diseases or coronary heart disease.
6
Funding: $120K
We use Machine learning to automatically derive accurate brain features (e.g. the volume of the hippocampus) from brain scans and compare them to a normative population. We also provide handy 2D and 3D visualisations of brain features. This not only saves time to neuroradiologists but also empowers them to make highly accurate reports, by using the latest techniques and findings in neurosciences
We use Machine learning to automatically derive accurate brain features (e.g. the volume of the hippocampus) from brain scans and compare them to a normative population. We also provide handy 2D and 3D visualisations of brain features. This not only saves time to neuroradiologists but also empowers them to make highly accurate reports, by using the latest techniques and findings in neurosciences
★
See also:
